New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect?

Journal of Rheumatology

Volumn 34, Issue 2, 2007, Pages 434-437

  Roux, Christian Hubert ^a,b   Brocq, Olivier ^a   Leccia, Nathalie ^a   Giacchero, Damien ^a   Breuil, Veronique ^a   Albert, Christine ^a   Lacour, Jean ^a   Perrin, Christophe ^a   Euler Ziegler, Liana ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Anti tumor necrosis factor ; Psoriatic palmoplantaris pustulosis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RHEUMATOID FACTOR;

ACANTHOSIS; ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE DURATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC PALMOPLANTARIS PUSTULOSIS; PUSTULOSIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DEFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; FEMALE; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846945388     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Flendrie M, Vissers W, Criemens M, De Jong E, De Kerkhof P, Van Riel P. Dermatological conditions during TNF blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76. Epub 2005 Apr 4.
2. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving TNF alpha antagonists. Ann Rheum Dis 2006;65:405-7. Epub 2005 Sep 8.
3. Sfikakis PF, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumour necrosis factor therapy. A paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-18.
4. Brocq O, Roux CH, Albert C, et al. Maintien thérapeutique des 3 anti TNF disponibles, dans la Polyarthrite Rhumatoïde (PR), la Spondylarthrite Ankylosante (SPA) et le Rhumatisme Psoriasique (RP): à propos de 571 prescriptions d'anti TNF chez 442 patients sur une période de 6 ans [abstract]. Rev Rhum 2005;72:918.
5. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor alpha therapy-induced vasculitis: cases series. J Rheumatol 2003;30:2287-91.
6. Baeten D, Kruithoff E, Van den Bosch F, et al. Systematic safety follow-up in a cohort of 107 patients treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
7. Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou J. Psoriatic lesions induced by anti-tumour necrosis factor alpha treatment: 2 new cases. Br J Dermatol 2004;150:506-7.
8. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-40.
9. Michaelson G, Kajermo U, Michaelson A, Hagforsen E. Infliximab can precipitate as well as worsen palmo plantar pustulosis: possible linkage to the expression of tumour necrosis factor alpha in the normal palmar eccrine sweat duct. Br J Dermatol 2005;153:1243-4.
10. Seneschal J, Heliot-Hosten I, Bouysou-Gauthier ML, et al. Eruption psoriasiforme sous anti-TNF alpha: un mécanisme toxidermique? [abstract]. Rev Rhum 2005;72:1009.
11. Zarnitsky C, Bravard P, Godon J, Alcaix D. Pustulose palmaire et plantaire chez une patiente traitée par adalimumab. Rev Rhum 2005;72 Pu 86:1195.
12. Solau-Gervais E, Lebas D, Duquesnoy B, Delaporte E, Flipo R. Cutaneous modifications during anti-TNF therapy in rheumatoid arthritis [abstract]. Ann Rheum Dis 2005;64 Suppl 111:458.
13. Djennane S, Oro S, Lévy-Weil FE, Sigal M, Feldman JL. Psoriasis cutané induit par traitement anti-TNF alpha au cours d'une fasciite éosinophile [abstract]. Rev Rhum 2005;72, 10-11, Pu 57:1183.
14. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor alpha antagonist therapy: a case series. J Rheumatol 2007;34:380-5. Epub 2006 Oct 1.
15. Massara A, Cavazzini PL, Trotta F. In Sapho syndrome anti-TNF alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology Oxford 2006;45:730-3. Epub 2006 Jan 10.
16. Barbaud A. Drug patch testing in systemic drug allergy. Toxicology 2005;209:209-16.
17. Keller M, Spanou Z, Schaerli P, et al. T cell regulated neutrophilic inflammation in auto-inflammatory diseases. J Immunol 2005;175:7678-86.
18. Asumalahiti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmo-plantar pustulosis. J Invest Dermatol 2003;120:627-32.
19. Benoist S, Toksoy A, Brocker EB, Gillitzer R, Gobeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004;150:1009-12.
20. Schmick K, Grabbe J. Recalcitrant generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor alpha antibody (infliximab) [letter]. Br J Dermatol 2004;150:367.